A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects.
Phase of Trial: Phase III
Latest Information Update: 27 Aug 2018
At a glance
- Drugs Ramelteon (Primary)
- Indications Bipolar I disorders
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 07 Feb 2014 Planned number of patients changed from 870 to 618 as reported by ClinicalTrials.gov.
- 24 Dec 2013 New source identified and integrated (United Kingdom Clinical Research Network : 12819)
- 18 Jun 2013 Planned end date changed from 1 Nov 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov record.